ライフサイエンスコーパス: -mismatched

1 for human leukocyte antigen (HLA)-A/-B/-DR 0-mismatched (0MM) kidneys, we analyzed the results of 264

2 0.77, P=0.05; IL-2RA:0.81, P=0.11) in HLA 0-mismatched recipients.

3 outcomes in human leukocyte antigen (HLA) 0-mismatched deceased donor kidney recipients.

4 In a fully H-2-mismatched, nonlymphopenic, immunocompetent mouse islet

5 2 is a 3' --> 5' exonuclease that removes 3'-mismatched sequences in a biochemical assay; however, it

6 In HLA-B*5703-mismatched recipients, the previously described early be

7 hed duplex vs ODN(CF3-(Ph)ImdC), while for A-mismatched duplex, only a 2-fold decrease was observed.

8 LDLT and ABO-mismatched transplantation constitute feasible options t

9 LDLT, including ABO-mismatched transplantation, constitutes a safe and effic

10 e of an HLA-mismatched donor and a major ABO-mismatched donor.

11 Survival of ABO-mismatched kidneys with stable renal function despite th

12 Using a minor histocompatibility Ag-mismatched BMT (B6 --> B6 x C3H.SW) followed by adoptive

13 atched, multiple minor histocompatibility Ag-mismatched C3H.SW-->B6 strain pairings.

14 MHC-matched but minor histocompatibility Ag-mismatched models driven by CD4 T cells.

15 in both MHC- and minor histocompatibility Ag-mismatched murine hemopoietic stem cell transplantation

16 ly responsible for the rejection of minor Ag-mismatched grafts has not yet been identified.

17 Instead, using age-mismatched nerve transplants in vivo, we show that the e

18 come in patients undergoing HLA-matched and -mismatched allo HCT for MDS.

19 human leukocyte antigen two DR-matched and -mismatched healthy volunteers and prekidney transplant d

20 ultiple clinically relevant MHC-matched and -mismatched murine models of GVHD, we investigated the ro

21 both human leukocyte antigen DR-matched and -mismatched pairs, particularly at therapeutic levels (>/

22 Graft survival of KIR-ligand-matched and -mismatched transplants was compared.

23 which adopts a novel differential and angle-mismatched polarizing optical design achieving wide-fiel

24 ng phenotypically HLA-identical or 1-antigen-mismatched relatives (related donors [RDs]).

25 unrelated donor (MUD, n = 152) or 1-antigen-mismatched unrelated adult donor (MMUD, n = 52) or 4-6/6

26 MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched mod

27 HC-matched, minor histocompatibility antigen-mismatched allogeneic chimeras with CML-like leukemia, i

28 ed multiple minor histocompatibility antigen-mismatched alloHCT using bone marrow (BM) cells and sple

29 d, multiple minor histocompatibility antigen-mismatched alloSCT, the most common type performed clini

30 In both a minor histocompatibility antigen-mismatched as well as a MHC-haploidentical model of scle

31 or multiple minor histocompatibility antigen-mismatched hematopoietic cell preparation.

32 nsfusion of minor histocompatibility antigen-mismatched platelets induced subsequent BMT rejection.

33 ated into a minor histocompatibility antigen-mismatched, T cell-depleted, allogeneic BMT mouse model.

34 ater with additional accumulation in antigen-mismatched tumors.

35 n patients receiving human leukocyte antigen-mismatched combined kidney and bone marrow transplantati

36 Fifteen human leukocyte antigen-mismatched living donor renal transplant recipients unde

37 co-cultures between human leukocyte antigen-mismatched peripheral blood lymphocytes from healthy adu

38 lation of CTLs after human leukocyte antigen-mismatched stem cell transplantation and may provide ant

39 ioning alloSCT using human leukocyte antigen-mismatched unrelated donors.

40 received CKBMT from human leukocyte antigen-mismatched, haploidentical living-related donors after m

41 mice also delayed rejection of major antigen-mismatched skin and MHC class II-mismatched cardiac allo

42 zed with CM before receiving a minor antigen-mismatched heart transplant exhibited potent DTH, T-cell

43 vant and received heterotopic, minor antigen-mismatched heart transplants.

44 ulted in prolonged survival of minor antigen-mismatched skin grafts.

45 ntibody was used in a multiple minor antigen-mismatched, BALB.B (H-2B) to C57BL/6 (H-2B), cardiac all

46 iently lysed antigen-matched but not antigen-mismatched targets 5 years after vaccination.

47 Single antigen-mismatched mouse model (C57BL/6 RIP-GP in C57BL/6) was u

48 of an RPBA cutoff with RPBA data) and assay-mismatched cutoffs (e.g., with the use of microbiologic

49 The application of assay-mismatched cutoffs leads to a misinterpretation of folat

50 ciency for assay-matched compared with assay-mismatched cutoffs were 35% compared with 56% (serum fol

51 ciency for assay-matched compared with assay-mismatched cutoffs were 5.6% compared with 16% (serum fo

52 ing a first 0 HLA-A, -B, -DR, or 0 HLA-A, -B-mismatched kidney transplant; contrariwise, there was a

53 tients became sensitized after a 0 HLA-A, -B-mismatched transplant, whereas the proportion rose up to

54 rence between the target and the single-base-mismatched DNA, resulting in a differential signal that

55 d inhibition with a stereotypic 'overlap-but-mismatched' pattern: the peaks of excitatory On/Off subf

56 lack criteria for donor selection when HLA-C-mismatched donors are a patient's only option for cure.

57 -host disease (GVHD) limits the use of HLA-C-mismatched unrelated donors in transplantation.

58 -C allotype in 1975 patients and their HLA-C-mismatched unrelated transplant donors.

59 VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 6

60 r partial calendar-time adjustment for clade-mismatched B/Wisconsin/01/2010-like virus (VE, 63%; 95%

61 using minor major histocompatibility complex-mismatched B6.C-H2 donor hearts in C57BL/6(H-2) recipien

62 rafted into major histocompatibility complex-mismatched BALB/c mice.

63 irradiated, major histocompatibility complex-mismatched CByB6F1 (F1) recipients failed to induce the

64 ) in both a major histocompatibility complex-mismatched clinically relevant BALB/c --> B6 model and m

65 ations from major histocompatibility complex-mismatched donors.

66 el of fully major histocompatibility complex-mismatched ectopic heart transplants.

67 a class II major histocompatibility complex-mismatched graft model to test the requirement for donor

68 d congenic, major histocompatibility complex-mismatched grafts developed without rejection in the abs

69 ammation in major histocompatibility complex-mismatched heart transplants.

70 Fully major histocompatibility complex-mismatched heterotopic heart transplantation (BALB/c to

71 ntly, fully major histocompatibility complex-mismatched islets were transplanted into naive diabetic

72 ontext of a major histocompatibility complex-mismatched liver transplant and in the context of liver

73 n GVHD in a major histocompatibility complex-mismatched model; however, their role when other host AP

74 Using the major histocompatibility complex-mismatched mouse orthotopic lung transplant model, we in

75 ngent fully major histocompatibility complex-mismatched murine skin allograft model to study graft su

76 plants, and major histocompatibility complex-mismatched porcine peripheral blood mononuclear cell.

77 ocytes were major histocompatibility complex-mismatched to the recipients (n = 3).

78 njection of major histocompatibility complex-mismatched UTC did not induce a detectable immune respon

79 o the fully major histocompatibility complex-mismatched WF rat recipients.

80 rs to fully major histocompatibility complex-mismatched Wistar Furth rat or C57 mouse recipients with

81 ing a fully major histocompatibility complex-mismatched, life-sustaining, murine model of renal allog

82 ur data demonstrate that GVHD after HLA-DPB1-mismatched CD4+ DLI can be mediated by allo-reactive HLA

83 4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT.

84 Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expressi

85 er when the recipient and donor are HLA-DPB1-mismatched, but the mechanisms leading to GVHD are unkno

86 absolute priority to all 000 HLA-A, -B, -DR-mismatched patients and well-matched pediatric patients

87 lower stimulation indices (SIs) than two DR-mismatched MLRs, 2 DR-matched MLRs generated more than t

88 Lewis rats received full-mismatched Brown Norway rat hindlimb transplants.

89 emic potential increases yearly when a group-mismatched HA subtype dominates seasonal influenza circu

90 D-related outcomes were higher in HLA-DP GVH-mismatched unrelated recipients than in HLA-matched sibl

91 potent antileukemic activity following haplo-mismatched, T cell-depleted stem cell transplantations f

92 Major histocompatibility-mismatched ACI (RT1) donors and Wistar Furth (WF) (RT1)

93 e from rejection of major histocompatibility-mismatched grafts toward long-term tolerance of donor gr

94 ection of major and minor histocompatibility-mismatched allografts performed in large-animal models r

95 t from MHC-matched, minor histocompatibility-mismatched donors; recipients of plerixafor mobilized pe

96 anting MHC-matched, minor histocompatibility-mismatched grafts composed of purified HSCs, HSCs plus b

97 loped a single human leukocyte antigen (HLA)-mismatched heterotopic murine heart transplant model (HL

98 grafting using human leukocyte antigen (HLA)-mismatched related donors.

99 nts, partially human leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bone ma

100 rejection of Human Leukocyte Antigens (HLA)-mismatched induced pluripotent stem cells (iPSCs) limits

101 HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cel

102 No grades 3 to 4 aGVHD occurred in 11 HLA-mismatched recipients in the 1.5 mg/m(2) group.

103 Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(+)TCR alphabeta/CD19 deplet

104 ecipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of multi

105 unique peripheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontransp

106 (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical sib

107 replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft-ver

108 s of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and dur

109 of the same target cells with activated HLA-mismatched mitogen-activated lymphomononuclear cells cau

110 re were no differences in survival after HLA-mismatched related, HLA-matched unrelated, or mismatched

111 Outcome after HLA-mismatched unrelated donor transplantation is influenced

112 eceptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impeded by

113 iral infections underwent an allogeneic, HLA-mismatched HSCT.

114 risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor.

115 cence (operational tolerance) against an HLA-mismatched graft, allowing them to withdraw all immunosu

116 acity may enable their persistence in an HLA-mismatched host.

117 h risk of GVHD, infection, or both in an HLA-mismatched setting.

118 HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98).

119 ty after receipt of a transplant from an HLA-mismatched unrelated donor.

120 polymorphisms in the unrelated HSCT and HLA-mismatched setting.

121 d unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007).

122 ut significant suppression of completely HLA-mismatched, Ag-induced proliferation.

123 isk of rejection over the first year for HLA-mismatched recipients (0.87, P<0.001).

124 n of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropriate p

125 afts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from

126 ives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors.

127 Simulations using 46 ICPs and 11 fully HLA-mismatched CPs were undertaken using the Australian KPD

128 suggesting that the allograft of Class I HLA-mismatched seropositive donors is inaccessible to CD8+ T

129 In HLA-mismatched HSCT, alloreactivity occurs when licensed don

130 -up in a phase IIb tolerance protocol in HLA-mismatched recipients of living donor kidney plus facili

131 sms for this, we compared the ability of HLA-mismatched CB and adult peripheral blood (PB) T cells to

132 -matched alloBMT and increase the use of HLA-mismatched related donors.

133 yte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch).

134 multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acute gr

135 ransplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also excluded.

136 ndergoing transplantation with partially HLA-mismatched unrelated donor umbilical cord blood were stu

137 that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vitro r

138 al for control of GVHD in T-cell-replete HLA-mismatched transplantation.

139 ads containing the corresponding donor's HLA-mismatched Ags.

140 ctive T cell repertoire for any specific HLA-mismatched donor-recipient pair.

141 atched set and relapse (P < .001) in the HLA-mismatched cohort.

142 ase, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazard ra

143 ociations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60; ha

144 d ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30; ha

145 he cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02; ha

146 phisms (SNPs) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNPs ar

147 HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the epi

148 Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute and

149 = 577) as well as to patients undergoing HLA-mismatched allo HCT.

150 ansgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT), NK

151 The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients wit

152 was alloantigen-specific expanded using HLA-mismatched immature, mature monocyte-derived dendritic c

153 om two patients were cotransplanted with HLA-mismatched human islets into immunodeficient mice.

154 We treated mice with HLA-mismatched mouse cardiac transplant with atorvastatin an

155 c T cells can have cross-reactivity with HLA-mismatched targets in vitro.

156 Life-threatening risks associated with HLA-mismatched unrelated donor hematopoietic cell transplant

157 ed 1.5 Gy whole body irradiation and class I-mismatched (SLA(gg) ) kidneys from naive pigs with or wi

158 to Mycobacterium tuberculosis in MHC class I-mismatched animals, as well as from Th1-biased dams to T

159 Similarly, whereas MHC class I-mismatched B6.K(d) hearts survived indefinitely and rema

160 rom major histocompatibility complex class I-mismatched donors using flow cytometry and immunohistoch

161 during the maintenance period after class I-mismatched Int-Tx, 5% to 10% myeloid chimerism was found

162 ransplant, group 1 (n = 3) underwent class I-mismatched kidney transplantation; group 2 (n = 3) under

163 oup 2 (n = 3) underwent 2 sequential class I-mismatched kidney transplantations; group 3 (n = 2) unde

164 we attempted to induce tolerance of class I-mismatched kidneys by adoptive transfer of cells and/or

165 miniature swine, which had accepted class I-mismatched kidneys long-term after 12 days of high-dose

166 ted long-term on animals tolerant of class I-mismatched kidneys, with the exception of epidermis, the

167 amino acid differences in single HLA class I-mismatched molecules, the probability of T cell alloreac

168 hanisms are involved in tolerance of class I-mismatched renal allografts in miniature swine treated w

169 underwent bilateral nephrectomy and class I-mismatched renal transplantation with a 12-day course of

170 ansplant arteriosclerosis in an MHC class II-mismatched allograft model.

171 contrast, chronic rejection of MHC class II-mismatched bm12 cardiac allografts was accelerated in Fc

172 by passenger CD4 T cells within MHC class II-mismatched bm12 heart grafts provokes antinuclear humora

173 jor antigen-mismatched skin and MHC class II-mismatched cardiac allografts.

174 in major histocompatibility complex class II-mismatched cardiac transplants.

175 Rejection was conserved across a class II-mismatched strain and when the earliest dissectable meta

176 t not female (HY(-)) recipients using MHC II-mismatched, parent-->F1, and miHAg-mismatched murine bon

177 Results Immune-mismatched stem cell implants demonstrated stronger feru

178 transplantation in rats from immunologically-mismatched inbred strains.

179 e of the composite waveguide at an impedance-mismatched fluidic interface, tunable sound transmission

180 189 days) and a significant expansion of KIR-mismatched NK cells (median, 5,800/mL of blood on day 14

181 e to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation

182 antisense oligonucleotides (ASOs): Bcl-x(L)-mismatched control and Bcl-x(L)-specific.

183 Lattice-mismatched core-shell quantum dots are expected to have

184 anocrystalline core (CdTe) to form a lattice-mismatched quantum dot can dramatically change the condu

185 xial semiconductor nanostructures in lattice-mismatched material systems.

186 vely to study stress distribution in lattice-mismatched semiconductor heterostructures.

187 is typically achieved via growth on lattice-mismatched substrates.

188 r Ge/Si should be relevant for other lattice-mismatched heterostructure systems, too.

189 xtend the supracrystalline growth to lattice-mismatched binary nanocrystal superlattices, in order to

190 th of epitaxial nanocomposites using lattice-mismatched constituents also enables strain-engineering,

191 und that co-reconstitution with 2 KIR ligand-mismatched compartments did not alter the frequency of K

192 ve killer cell Ig-like receptor (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation

193 A/H3N2, and further reduced against lineage-mismatched influenza B.

194 ia and 27% (95% CI, -21% to 56%) for lineage-mismatched B/Yamagata.

195 sgenic mouse line (Mos-iCsp3) in which a lox-mismatched Cre/lox cassette can be activated to produce

196 in a minor histocompatibility antigen (mHA)-mismatched mouse model.

197 r histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marr

198 HD in major histocompatibility complex (MHC)-mismatched and MHC-matched BMT following conditioning wi

199 al of major histocompatibility complex (MHC)-mismatched cardiac allografts.

200 on of major histocompatibility complex (MHC)-mismatched mixed chimerism reversed autoimmunity and ree

201 n the major histocompatibility complex (MHC)-mismatched pairs, that T cell restricted proliferative r

202 ve to major histocompatibility complex (MHC)-mismatched stimulators and suppress allogeneic responses

203 from major histocompatibility complex (MHC)-mismatched VIP-knockout (KO) or wild-type donors, and tr

204 full major histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cel

205 sociated with an immune response against MHC-mismatched grafted cells.

206 nhibit the indirect alloresponse against MHC-mismatched skin grafts and hence the generation of IgG a

207 Using an MHC-mismatched model of acute GVHD, in the present study we

208 Here we report that, in an MHC-mismatched model of C57BL/6 donor to BALB/c recipient, W

209 cute GVHD models with C57BL/6 donors and MHC-mismatched BALB/c recipients and with C3H.SW donors and

210 e or IFN-gamma(-/-) counterparts in both MHC-mismatched and MHC-matched but minor histocompatibility

211 ve TCRs with endogenous TCRalpha-chains; MHC-mismatched H-2(b) but not matched H-2(g7) mixed chimeris

212 duce high titers of antibody to complete MHC-mismatched heart and renal allografts.

213 nfected with m3KODeltanef than in either MHC-mismatched MCMs infected with m3KODeltanef or MCMs infec

214 trials of TLI/ATG/alkylator regimens for MHC-mismatched BMT for hemoglobinopathies.

215 ).BDC2.5 TCD BM cells with BM cells from MHC-mismatched T cell-deficient C57BL/6 mice into lethally i

216 tion; and group 4 (n = 2) underwent full MHC-mismatched heart/kidney transplantation.

217 inite islet allograft survival in a full MHC-mismatched model without the need for any immunosuppress

218 ces long-term allograft survival in full MHC-mismatched models of allogeneic islet and cardiac transp

219 ced CD8(+) Foxp3(+) T cells protect full MHC-mismatched skin allografts.

220 recipients spontaneously accepted fully MHC-mismatched A/J renal allografts, recipients containing d

221 poietic chimerism in recipients of fully MHC-mismatched allogeneic bone marrow cells with anti-CD154

222 C57BL/6 recipients receiving a fully MHC-mismatched BALB/c heart graft treated with CTLA4Ig + don

223 nts treated with CTLA4-Ig rejected fully MHC-mismatched BALB/c heart transplants, treatment of IL-6-d

224 howed that CC (PEG MG) islets from fully MHC-mismatched Balb/c mice supported long-term (>100 days) s

225 Tregs led to long-term survival of fully MHC-mismatched cardiac allografts, and prevented development

226 Fully MHC-mismatched heart allografts were transplanted into three

227 Aorta transplantation between fully MHC-mismatched mice in association with intravenous LG3 inje

228 ival of cardiac allografts in this fully MHC-mismatched model, it significantly prolonged graft survi

229 en-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marrow transplantation.

230 mits the induction of tolerance to fully MHC-mismatched renal transplants in miniature swine.

231 monotherapy prolonged survival of fully MHC-mismatched vascularized mouse cardiac allografts.

232 ere, we studied TLR signaling in a fully MHC-mismatched, life-sustaining murine model of kidney allog

233 group 3 (n = 2) underwent haploidentical MHC-mismatched heart/kidney transplantation; and group 4 (n

234 lecular targets in vivo was confirmed in MHC-mismatched experimental BMT.

235 c T cells, can be positively selected in MHC-mismatched H-2(b) thymus.

236 ies used high doses of CD4(+) T cells in MHC-mismatched models that caused rapid and lethal GVHD.

237 ular perfusion and tissue oxygenation in MHC-mismatched transplants.

238 /-).BDC2.5 mice into lethally irradiated MHC-mismatched H-2(b) C57BL/6 or MHC-matched congenic B6.H-2

239 , and caused ameliorated GVHD in a major MHC-mismatched model of HCT.

240 In a murine MHC-mismatched BM transplantation model, we observed that IL

241 Despite these observations, using murine MHC-mismatched skin and heart transplant models, donor-deriv

242 deficiency exhibit delayed rejection of MHC-mismatched cardiac grafts.

243 Using a murine model of MHC-mismatched cardiac transplantation, we investigated the

244 Using a mouse model of MHC-mismatched heart transplantation, we report markedly pro

245 Therefore, induction of MHC-mismatched mixed chimerism depletes pre-existing and de

246 Induction of MHC-mismatched mixed chimerism results in depleting host-typ

247 ctive transgenic T cells is dependent on MHC-mismatched donor BM-derived APCs but not on donor BM-der

248 induced long-term survival of partially MHC-mismatched heart grafts when combined with short-term ad

249 erant to 'self' and capable of rejecting MHC-mismatched skin allografts.

250 Subsequently, MHC-mismatched macaques underwent intraportal allogeneic isl

251 aken together, our studies indicate that MHC-mismatched mixed chimerism can mediate thymic deletion o

252 Our recent studies suggest that MHC-mismatched mixed chimerism mediates negative selection o

253 imed to alloantigens mediate GVHD in the MHC-mismatched C57BL/6 (B6)-->BALB/c and the MHC-matched, mu

254 uced lethal GVHD on adoptive transfer to MHC-mismatched hosts.

255 pression and donor-specific tolerance to MHC-mismatched organ grafts are important clinical goals.

256 on, we studied rhesus monkeys undergoing MHC-mismatched islet allotransplants treated with belatacept

257 ived saline (negative control), unsorted MHC-mismatched PBMC (positive control), PBMC enriched with C

258 either mixed or complete chimerism with MHC-mismatched BM transplants prevented T1D in such mice.

259 Induction of mixed chimerism with MHC-mismatched, but not matched, donor BM transplants re-est

260 strointestinal aGVHD was also higher in MICA-mismatched patients (35% vs 17%, P = .05).

261 r rate of grade II-IV aGVHD was seen in MICA-mismatched patients (80% vs 40%, P = .003) irrespective

262 -matched, minor histocompatibility Ag (miHA)-mismatched B10.BR-->CBA strain combination has been used

263 ng MHC II-mismatched, parent-->F1, and miHAg-mismatched murine bone marrow transplantation models.

264 potential of IFNgammaR(-/-) Tconv in a minor-mismatched GVHD model.

265 histocompatibility complex major- and minor-mismatched murine model significantly delayed the onset

266 or histocompatibility complex-matched, minor-mismatched C3H.SW --> B6 model of GVHD.

267 at transplant centers give priority to GVH-O-mismatched units over other mismatches and avoid selecti

268 nsgenic BDC2.5-NOD mice with MHC-matched or -mismatched MHC II(-/-) BM transplants failed to induce t

269 ted by CD4+ T cells directed against patient-mismatched HLA-DPB1 molecules on hematopoietic cells and

270 ase-matched alternans gradually become phase-mismatched, via the formation and movement of nodes.

271 of nodes, which are junctures between phase-mismatched cell regions.

272 CaTs can form spatially phase-mismatched alternans patterns after the first few beats

273 aT alternans can also become spatially phase-mismatched within a single cell, when one part of the ce

274 and spatiotemporal evolution of these phase-mismatched patterns are not known.

275 s that use ecologically- and physiologically-mismatched diets over-estimate susceptibility and under-

276 fibrosis progression in this high-risk race-mismatched group need to be investigated.

277 ly transplanted to mixed lymphocyte reaction-mismatched Cynomolgus macaques.

278 after the first MVA-CMDR boost, the sequence-mismatched DNA-prime MVA-boost vaccine strategy induced

279 conclude that immune responses to "sequence-mismatched" FVIII products are unlikely to contribute ap

280 In 3 of 4 sex-mismatched specimens, tissue XY-karyotyping of the RPM i

281 d endomyocardial biopsy specimens from 7 sex-mismatched (female donor heart to a male recipient) hear

282 iver biopsy samples of 14 patients after sex-mismatched (female-to-male) liver transplantation were i

283 udied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation

284 cute graft-versus-host disease following sex-mismatched HLA-identical bone marrow transplantation.

285 bridization demonstrated rare cells from sex-mismatched donors.

286 transplantation of a minor antigen (HY) sex-mismatched heart graft, the lymphatic flow index was sig

287 investigate the origin of hepatocytes in sex-mismatched cases of orthotopic liver transplantation in

288 graft dendritic cells was sought in nine sex-mismatched recipients using XY fluorescence in situ hybr

289 Because clinical data suggest that sex-mismatched H-Y Ags may be important minor histocompatibi

290 rmed from seeded scaffold anastomosed to sex-mismatched natural vessel segments, we demonstrate that

291 in female mice that previously underwent sex-mismatched bone marrow transplantation from enhanced gre

292 In addition, we demonstrate using sex-mismatched chimeric hosts that bone marrow is not a sign

293 ts complexes with perfect-matched and single-mismatched complementary DNA molecules were examined by

294 NA distinguishing perfect-matched and single-mismatched target DNA molecules to the best extent, like

295 s a new alternative strategy for doping size-mismatched functional atoms into wide band-gap materials

296 arly interstitial fibrosis (r<0.45) for size-mismatched allograft recipients.

297 ed and one was overlooked when using subtype-mismatched pMHC multimer collections.

298 tively resolve neighboring pairs of symmetry-mismatched layers of the portal vertex.

299 of its N-terminal loops, which the symmetry-mismatched binding of ClpA suffices to induce.

300 pression by NK cells is required for in vivo-mismatched bone marrow allograft rejection as well as fo